focus -WSS

focus

author：fashion 2025-09-02 11:48:36 - browse：97

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Pregnancy ages women, but effects reverse after delivery

WSS

Adam's Take: Intra

STAT Summit: Michael J. Fox on progress in Parkinson's research

Solve the antibiotic resistance crisis with preventive drugs

Researchers explore possible ties between long Covid, menopause

CEOs share strategies for surviving biotech slump

Bring on the sabbaticals for nurses

hotspot

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Studies point to risks of excluding people with obesity from drug trials

As demand for Covid shots wanes, Moderna seeks its next success

Pharmacists can make shortage drugs, but at what cost?

New air purifier tech could be key to improving indoor air quality

Senate committee scrutinizes Medicare Advantage brokers

What does generative AI mean for health care? We asked experts

With Wegovy coverage, Medicare patients may face high costs

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Biotech founders on deal

knowledge

Why health workers in Gaza are injured or die at high rates

Medicare reduced heart disease by changing how it pays doctors

The explosion of genetic testing requires a new approach

HHS leader on health, climate change and biopharma emissions

How climate

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

leisure time

hotspot

hotspot